### HIGHLIGHTS

**3267**  
Selected Articles from This Issue

### SPECIAL FEATURES

**CCR Translations**

**3269**  
A PERFECT Biomarker-focused Study of Neoadjuvant IO for Esophageal Gastric Cancer  
Daniel V.T. Catenacci  
See related article, p. 3351

**3272**  
Molecular Subtypes of Pancreatic Cancer: A Proteomics Approach  
Ravi Thakur and Pankaj K. Singh  
See related article, p. 3370

**3275**  
Answers Are in the Blood: cfDNA to Enhance Precision Medicine for Breast Cancer  
Hope S. Rugo and Laura Huppert  
See related article, p. 3404

**3278**  
Can Biomarkers Guide Oncolytic Virus Immunotherapy?  
Howard L. Kaufman  
See related article, p. 3432

### Reviews

**3280**  
APOBEC and Cancer Viroimmunotherapy: Thinking the Unthinkable  
Richard G. Vile, Alan Melcher, Hardev Pandha, Kevin J. Harrington, and Jose S. Pulido

**3291**  
Therapeutic Manipulation of Tumor-associated Macrophages: Facts and Hopes from a Clinical and Translational Perspective  
Paola Alleva, Clément Anfray, Aldo Ummarino, and Fernando Torres Andón

### CLINICAL TRIALS: TARGETED THERAPY

**3298**  
Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas  

**3307**  
Selinexor in Combination with R-CHOP for Frontline Treatment of Non-Hodgkin Lymphoma: Results of a Phase I Study  
Erlene K. Seymour, Husain Yar Khan, Yiwei Li, Mahmoud Chaker, Irfana Muqbil, Amro Aboukameel, Radhakrishanan Ramchandren, Christiane Houde, Golbon Sterbis, Jay Yang, Divya Bhutani, Silvana Pregia, Kathy Reichel, Amy Huddlestun, Colleen Neveux, Kelly Corona, Yosef Landesman, Jatin Shah, Michael Kaufman, Sharon Shacham, Ramzi M. Mohammad, Asfar S. Azmi, and Jeffrey A. Zonder

**3317**  
Angiokines Associated with Targeted Therapy Outcomes in Patients with Non-Clear Cell Renal Cell Carcinoma  
3329  Sapanisertib Plus Exemestane or Fulvestrant in Women with Hormone Receptor–Positive/HER2-Negative Advanced or Metastatic Breast Cancer

Bora Lim, David A. Potter, Mohammad A. Salkeni, Paula Silverman, Tufia C. Haddad, Frederic Forget, Ahmad Awada, Jean-Luc Canon, Michael Danso, Alain Lortholary, Hugues Bourgeois, Elizabeth Tan-Chiu, Sylvie Vincent, Brittany Bahamon, Kevin J. Galinsky, Chirag Patel, Rachel Neuwirth, E. Jane Leonard, and Jennifer R. Diamond

CLINICAL TRIALS: IMMUNOTHERAPY

3339  Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma


3351  Neoadjuvant Chemoradiotherapy Combined with Atezolizumab for Resectable Esophageal Adenocarcinoma: A Single-arm Phase II Feasibility Trial (PERFECT)


See related commentary, p. 3269

3360  Safety and Clinical Activity of Atezolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer: A Phase I Study


See related commentary, p. 3269

3370  A Clinically Applicable 24-Protein Model for Classifying Risk Subgroups in Pancreatic Ductal Adenocarcinomas using Multiple Reaction Monitoring-Mass Spectrometry

Minsoo Son, Hongbeom Kim, Dohyun Han, Yoseop Kim, Iksoo Huh, Youngmin Han, Seung-Mo Hong, Woon Kwon, Haeryoung Kim, Jin-Young Jang, and Youngsoo Kim

See related commentary, p. 3272

3383  Integrative Genomic Analysis of Gemcitabine Resistance in Pancreatic Cancer by Patient-derived Xenograft Models

Gang Yang, Wenfang Guan, Zhe Cao, Wenbo Guo, Guangbing Xiong, Fangyu Zhao, Mengyu Feng, Jiandong Qiu, Yuee Liu, Michael Q. Zhang, Lei You, Taiping Zhang, Yuepei Zhao, and Jin Gu

See related commentary, p. 3272

3397  Plasma KIM-1 Is Associated with Recurrence Risk after Nephrectomy for Localized Renal Cell Carcinoma: A Trial of the ECOG-ACRIN Research Group (E2805)

Wenxin Xu, Maneka Puligandla, Brian Halbert, Naomi B. Haas, Keith T. Flaherty, Robert G. Uzzo, Janice P. Dutcher, Robert S. DiPaolo, Venkata Sabbisetti, and Rupal S. Bhatt

3404  Tumor Tissue- versus Plasma-based Genotyping for Selection of Matched Therapy and Impact on Clinical Outcomes in Patients with Metastatic Breast Cancer

Neelima Vidula, Andrzej Niemierko, Giuliana Malvarosa, Megan Yuen, Jochen Lennerz, A. John Iafrate, Seth A. Wander, Laura Spring, Dejan Juric, Steven Isakoff, Jerry Younger, Beverly Moy, Leif W. Ellisen, and Aditya Bardia

See related commentary, p. 3275

3414  Development and Validation of a Novel Nomogram for Individualized Prediction of Survival in Cancer of Unknown Primary


3422  Artificial Intelligence–Assisted Amphiregulin and Epiregulin IHC Predicts Panitumumab Benefit in RAS Wild-Type Metastatic Colorectal Cancer

Christopher J.M. Williams, Jenny F. Seligmann, Faye Elliott, Michael Shires, Susan D. Richman, Sarah Brown, Liping Zhang, Shalini Singh, Judith Pugh, Xiao-Meng Xu, Andrea Muranyi, Christoph Guetter, Auranach Lorsakul, Uday Kurkure, Zuo Zhao, Jim Martin, Xingwei Wang, Kien Nguyen, Wen-Wei Liu, Dongyao Yan, Nicholas P. West, Jennifer H. Barrett, Michael Barnes, Isaac Bai, Matthew T. Seymour, Philip Quirke, and Kandavel Shanmugam

Downloaded from clincancerres.aacrjournals.org on August 21, 2021. © 2021 American Association for Cancer Research.
Mutations in the IFN-γ-JAK-STAT Pathway Causing Resistance to Immune Checkpoint Inhibitors in Melanoma Increase Sensitivity to Oncolytic Virus Treatment
Tan-Trieu Nguyen, LeeAnn Ramsay, Mozhdeh Ahanfesh-Adams, Mathieu Lajoie, Dirk Schadendorf, Tommy Alain, and Ian R. Watson
See related commentary, p. 3278

Impact of Baseline and On-Treatment Glycemia on Everolimus-Exemestane Efficacy in Patients with Hormone Receptor–Positive Advanced Breast Cancer (EVERMET)
Claudio Vernieri, Federico Nichetti, Luca Lalli, Luca Moscetti, Carlo Alberto Giorgi, Gaia Griguolo, Antonio Marra, Giovanni Randon, Carmen G. Rea, Francesca Ligorio, Simone Scagnoli, Claudia De Angelis, Chiara Molinelli, Agnese Fabbri, Emanuela Ferrari, Dario Trapani, Andrea Milani, Elisa Agostinetti, Ottavia Bernocchi, Giovanna Catania, Amelia Vantaggiato, Michela Palleschi, Anna Moretti, Debora Basile, Marika Cinausero, Arta Ajazi, Lorenzo Castagnoli, Salvatore Lo Vullo, Lorenzo Gerratana, Fabio Puglisi, Nicla La Verde, Grazia Arpino, Andrea Rocca, Mariangela Ciccarese, Rebecca Pedersini, Alessandra Fabi, Daniele Generali, Agnese Losurdo, Filippo Montemurro, Giuseppe Curigliano, Lucia Del Mastro, Andrea Michelotti, Enrico Cortesi, Valentina Guarnieri, Giancarlo Pruneri, Luigi Mariani, and Filippo de Braud

Therapeutic Efficacy of Combined JAK1/2, Pan-PIM, and CDK4/6 Inhibition in Myeloproliferative Neoplasms
Raajit K. Rampal, Maria Pinzon-Ortiz, Amritha Varshini Hansasoge Somasundara, Benjamin Durham, Richard Koche, Barbara Spitzer, Shoron Mowla, Ashwaryya Krishnan, Bing Li, Wenbin An, Andriy Derkach, Sean Devlin, Xin Hui Rong, Tyler Longmire, Shara Esther Eisman, Keith Cordner, Justin T. Whitfield, Gary Vanasse, Zhu A. Cao, and Ross L. Levine

High PDGFRb Expression Predicts Resistance to Radiotherapy in DCIS within the SweDCIS Randomized Trial
Carina Strell, Dick Folkvaljon, Erik Holmberg, Aglaia Schiza, Viktoria Thurfjell, Per Karlsson, Jonas Bergh, Troy Bremer, Lars A. Akslen, Fredrik Wärnberg, and Arne Ostman

High PDGFRb Expression Predicts Resistance to Radiotherapy in DCIS within the SweDCIS Randomized Trial
Carina Strell, Dick Folkvaljon, Erik Holmberg, Aglaia Schiza, Viktoria Thurfjell, Per Karlsson, Jonas Bergh, Troy Bremer, Lars A. Akslen, Fredrik Wärnberg, and Arne Ostman

Next-Generation Sequencing of 487 Esophageal Adenocarcinomas Reveals Independently Prognostic Genomic Driver Alterations and Pathways
ABOUT THE COVER

The cover shows an image of a mpMRI-visible PCa tumor analyzed using AI-driven analysis. This tumor has glandular structures composed of malignant cells that represent stroma and compact tumor architecture. Macrophage infiltration is pronounced in the malignant zones, whereas T-cell infiltration primarily is observed in the nonmalignant compartment. For details, see the article by Pachynski and colleagues on page 3478 of this issue.